Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

Alnylam shares remain roughly 40% below their peak after falling more than 50% year-to-date earlier in 2026 following a Q2 revenue-guidance cut, but 22 of 29 analysts rate the stock buy or strong buy and see about 50% 12-month upside. The bullish thesis rests on 72% year-over-year Q2 revenue growth, expected 75% full-year 2026 growth, reduced competitive pressure in ATTR-CM after AstraZeneca's Wainua setback, and a clearer runway for Amvuttra through Pfizer's U.S. generic exposure beginning in mid-2031. At approximately 6.8x projected 2026 sales, 19.5x forward earnings, and a 0.32 PEG ratio, the article argues the post-selloff valuation offers attractive risk-reward, though it remains dependent on nucresiran's clinical and commercial success.

Analysis

ALNY’s valuation discount is only attractive if the guidance reset proves to be a temporary launch/access issue rather than evidence of slower ATTR-CM share capture. The relevant near-term KPI is sequential Amvuttra patient starts and persistence, not headline revenue growth: any further downgrade would expose that the market is assigning a lower terminal penetration rate to a franchise competing against an entrenched branded standard of care.

The apparent reduction in pipeline competition is directionally positive, but it should not be capitalized as a full probability-of-success gain for nucresiran. A rival RNA-silencing setback can also raise questions around endpoint selection, patient mix, and the difficulty of demonstrating differentiated outcomes in ATTR-CM; ALNY will need to show its mechanism produces a sufficiently differentiated efficacy, dosing, or safety profile to overcome incumbent physician inertia. PFE remains the commercial incumbent risk even without generic entry, with substantial ability to defend accounts through contracting and field-force intensity.

Positioning is the more immediate opportunity: overwhelmingly constructive sell-side ratings after a large drawdown create asymmetric upside if the next earnings report restores confidence in the revenue trajectory, but also leave limited analyst-support downside protection if guidance slips again. Over 1-3 months, stabilization in scripts and reiteration of the commercial outlook could drive multiple recovery; over 6-18 months, the stock will trade increasingly on clinical de-risking and the credibility of its next-wave RNAi pipeline rather than the current earnings multiple.

Key Decisions for Investors

• Watch-list ALNY for a long entry following the next quarterly update only if management reaffirms full-year guidance and reports sequential acceleration in Amvuttra demand metrics; target a 20-30% rerating over 3-6 months versus a 10-15% stop on a renewed guidance cut.
• For event-driven exposure, prefer a defined-risk ALNY call spread expiring after the next earnings release rather than outright stock ahead of unverified demand data; size only after implied volatility is compared with ALNY’s prior post-earnings moves.
• Avoid using PFE as a clean short hedge: its ATTR economics are too small relative to the broader portfolio. A better hedge for an ALNY long is position sizing or put protection, with downside thesis invalidated by sustained Amvuttra script acceleration.
• Treat any pipeline-driven rally as provisional until disclosed trial design, endpoint differentiation, and safety data support a higher probability of success; reduce exposure if management delays expected development milestones or reframes the ATTR-CM launch path.